<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00292162</url>
  </required_header>
  <id_info>
    <org_study_id>05/S0704/47</org_study_id>
    <nct_id>NCT00292162</nct_id>
  </id_info>
  <brief_title>Curing Atrial Fibrillation in Heart Failure</brief_title>
  <official_title>Radiofrequency Ablation for Atrial Fibrillation in Advanced Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NHS Greater Glasgow and Clyde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NHS Greater Glasgow and Clyde</source>
  <brief_summary>
    <textblock>
      Heart failure is a condition that occurs when the heart muscle weakens and no longer
      contracts normally. Half of these patients have an irregularity of heart rhythm called atrial
      fibrillation (AF). Patients with both heart failure and AF spend more time in hospital, and
      die earlier than those with heart failure alone. AF is difficult to treat with conventional
      methods in patients with heart failure. Radiofrequency ablation is a new technique used to
      cure AF. The investigators aim to establish if radiofrequency ablation for atrial
      fibrillation in patients with advanced heart failure can result in marked improvement in the
      function of the heart.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)%</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>left ventricular ejection fraction (LVEF) is a measure of the % of blood ejected from the ventricle in one heart beat. It is a measure of cardiac function. We measured LVEF at baseline and at 6 months, to assess whether there had been a change in the patients cardiac function over time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)in %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Left Ventricular Ejection Fraction as measured by Magnetic Resonance Imaging (MRI)at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma B-type Natriuretic Peptide (BNP)</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>venous blood taken to assess levels of the above peptide. High evels of the peptide are associated with adverse prognosis. Blood levels are taken at baseline and 6 months. The change over 6 months is assessed, thereore it is possible to have a negative number if the level falls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma B-type Natriuretic Peptide (BNP) at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Plasma B-type Natriuretic Peptide (BNP) measured at basline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma B-type Natriuretic Peptide (BNP) at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Plasma B-type Natriuretic Peptide (BNP)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Chronic Heart Failure</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>medical therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard therapy for heart failure with angiotensin converting enzyme inhibitors(ACE) - (Ramipril, enalapril, lisinopril, captopril, perindopril), beta-blocker (BB) - (carvedilol, bisoprolol, metoprolol), Aldosterone antagonists (spironolactone) +/- diuretics and digoxin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiofrequency ablation (RFA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isolation of the pulmonary veins using radiofrequency ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiofrequency ablation</intervention_name>
    <description>isolation of the pulmonary veins with radiofrequency ablation (RFA)</description>
    <arm_group_label>Radiofrequency ablation (RFA)</arm_group_label>
    <other_name>radiofrequency ablation (RFA)</other_name>
    <other_name>pulmonary vein isolation (PVI)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril</intervention_name>
    <description>Evidence based treatment for heart failure. Dose and type will depend on patient tolerability.</description>
    <arm_group_label>medical therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol</intervention_name>
    <description>Evidence based treatment for heart failure. Dose and type will depend on patient tolerance.</description>
    <arm_group_label>medical therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aldosterone Antagonists - spironolactone</intervention_name>
    <description>Evidence based treatment for heart failure. Dose and type will depend on patient to treatment.</description>
    <arm_group_label>medical therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Persistent atrial fibrillation (AF)

          -  New York Heart Association (NYHA) II, III and IV chronic heart failure (CHF) despite
             optimal medical therapy for at least 3 months

          -  left ventricular ejection fraction (LVEF) &lt;35% - as measured by radionuclide
             ventriculography (RNVG)

          -  Patients with CHF secondary to ischaemic and non-ischaemic aetiology

        Exclusion Criteria:

          -  QRS duration &gt;150ms (or QRS 120-150 with evidence of mechanical cardiac dysynchrony)

          -  Magnetic resonance imaging (MRI) - incompatible metallic (ferrous) prosthesis

          -  Primary valvular disease as a cause of CHF

          -  Reversible causes of CHF

          -  Acute myocarditis

          -  Patients aged 18 or less

          -  Patients having undergone revascularisation procedures within 6 months

          -  Paroxysmal AF

          -  Pregnancy

          -  Expected cardiac transplantation within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek T Connelly, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glasgow Royal Infirmary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glasgow Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G31 2ER</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2006</study_first_submitted>
  <study_first_submitted_qc>February 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2006</study_first_posted>
  <results_first_submitted>August 1, 2011</results_first_submitted>
  <results_first_submitted_qc>May 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 1, 2012</results_first_posted>
  <last_update_submitted>May 29, 2012</last_update_submitted>
  <last_update_submitted_qc>May 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NHS Greater Glasgow and Clyde</investigator_affiliation>
    <investigator_full_name>Michael MacDonald</investigator_full_name>
    <investigator_title>Cardiology ST6</investigator_title>
  </responsible_party>
  <keyword>Chronic Heart Failure</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Radiofrequency Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Bisoprolol</mesh_term>
    <mesh_term>Perindopril</mesh_term>
    <mesh_term>Captopril</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Medical Therapy</title>
          <description>This consisted of standard treatment of heart failure as per international guidelines. Treatment generally included use of ace-inhibitors (captopril, enalapril, lisinopril, perindopril, ramipril), beta blocker (metoprolol, carvedilol, bisoprolol) and aldosterone antagonists (spironolactone). Obviously actual combination dose and type of drug used dependent on patient comorbidity and tolerance.</description>
        </group>
        <group group_id="P2">
          <title>Radiofrequency Ablation</title>
          <description>Patients underwent isolation of the pulmonary veins with radiofrequency ablation. This was performed a maximum of 2 times to try to acheive sinus rhythm. All patients also received background heart failure treatment as per international guidelines.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Medical Therapy</title>
          <description>This consisted of standard treatment of heart failure as per international guidelines. Treatment generally included use of ace-inhibitors (captopril, enalapril, lisinopril, perindopril, ramipril), beta blocker (metoprolol, carvedilol, bisoprolol) and aldosterone antagonists (spironolactone). Obviously actual combination dose and type of drug used dependent on patient comorbidity and tolerance.</description>
        </group>
        <group group_id="B2">
          <title>Radiofrequency Ablation</title>
          <description>Patients underwent isolation of the pulmonary veins with radiofrequency ablation. This was performed a maximum of 2 times to try to acheive sinus rhythm. All patients also received background heart failure treatment as per international guidelines.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="8"/>
                    <measurement group_id="B2" value="62" spread="6.7"/>
                    <measurement group_id="B3" value="63" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)%</title>
        <description>left ventricular ejection fraction (LVEF) is a measure of the % of blood ejected from the ventricle in one heart beat. It is a measure of cardiac function. We measured LVEF at baseline and at 6 months, to assess whether there had been a change in the patients cardiac function over time.</description>
        <time_frame>baseline and 6 months</time_frame>
        <population>Number of patients analyzed is different from number of patients enrolled because some of the outcomes could not be measured in some patients ie the patient did not tolerate an mri or dropped out of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Medical Therapy</title>
            <description>This consisted of standard treatment of heart failure as per international guidelines. Treatment generally included use of ace-inhibitors (captopril, enalapril, lisinopril, perindopril, ramipril), beta blocker (metoprolol, carvedilol, bisoprolol) and aldosterone antagonists (spironolactone). Obviously actual combination dose and type of drug used dependent on patient comorbidity and tolerance.</description>
          </group>
          <group group_id="O2">
            <title>Radiofrequency Ablation</title>
            <description>Patients underwent isolation of the pulmonary veins with radiofrequency ablation. This was performed a maximum of 2 times to try to acheive sinus rhythm. All patients also received background heart failure treatment as per international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)%</title>
          <description>left ventricular ejection fraction (LVEF) is a measure of the % of blood ejected from the ventricle in one heart beat. It is a measure of cardiac function. We measured LVEF at baseline and at 6 months, to assess whether there had been a change in the patients cardiac function over time.</description>
          <population>Number of patients analyzed is different from number of patients enrolled because some of the outcomes could not be measured in some patients ie the patient did not tolerate an mri or dropped out of the study</population>
          <units>percentage of blood ejected in one beat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="6.8"/>
                    <measurement group_id="O2" value="4.5" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma B-type Natriuretic Peptide (BNP)</title>
        <description>venous blood taken to assess levels of the above peptide. High evels of the peptide are associated with adverse prognosis. Blood levels are taken at baseline and 6 months. The change over 6 months is assessed, thereore it is possible to have a negative number if the level falls.</description>
        <time_frame>baseline and 6 months</time_frame>
        <population>Number of patients analyzed is different from number of patients enrolled because some of the outcomes could not be measured in some patients ie the patient did not tolerate a blood test or dropped out of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Medical Therapy</title>
            <description>This consisted of standard treatment of heart failure as per international guidelines. Treatment generally included use of ace-inhibitors (captopril, enalapril, lisinopril, perindopril, ramipril), beta blocker (metoprolol, carvedilol, bisoprolol) and aldosterone antagonists (spironolactone). Obviously actual combination dose and type of drug used dependent on patient comorbidity and tolerance.</description>
          </group>
          <group group_id="O2">
            <title>Radiofrequency Ablation</title>
            <description>Patients underwent isolation of the pulmonary veins with radiofrequency ablation. This was performed a maximum of 2 times to try to acheive sinus rhythm. All patients also received background heart failure treatment as per international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma B-type Natriuretic Peptide (BNP)</title>
          <description>venous blood taken to assess levels of the above peptide. High evels of the peptide are associated with adverse prognosis. Blood levels are taken at baseline and 6 months. The change over 6 months is assessed, thereore it is possible to have a negative number if the level falls.</description>
          <population>Number of patients analyzed is different from number of patients enrolled because some of the outcomes could not be measured in some patients ie the patient did not tolerate a blood test or dropped out of the study</population>
          <units>picograms per millilitre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" spread="648" lower_limit="-563" upper_limit="733"/>
                    <measurement group_id="O2" value="-196" spread="1469" lower_limit="-1665" upper_limit="1273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)</title>
        <description>Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)in %</description>
        <time_frame>Baseline</time_frame>
        <population>Number of patients analyzed is different from number of patients enrolled because some of the outcomes could not be measured in some patients ie the patient did not tolerate an mri or dropped out of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Medical Therapy</title>
            <description>This consisted of standard treatment of heart failure as per international guidelines. Treatment generally included use of ace-inhibitors (captopril, enalapril, lisinopril, perindopril, ramipril), beta blocker (metoprolol, carvedilol, bisoprolol) and aldosterone antagonists (spironolactone). Obviously actual combination dose and type of drug used dependent on patient comorbidity and tolerance.</description>
          </group>
          <group group_id="O2">
            <title>Radiofrequency Ablation</title>
            <description>Patients underwent isolation of the pulmonary veins with radiofrequency ablation. This was performed a maximum of 2 times to try to acheive sinus rhythm. All patients also received background heart failure treatment as per international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)</title>
          <description>Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)in %</description>
          <population>Number of patients analyzed is different from number of patients enrolled because some of the outcomes could not be measured in some patients ie the patient did not tolerate an mri or dropped out of the study</population>
          <units>percentage of blood ejected in one beat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" spread="10" lower_limit="33" upper_limit="53"/>
                    <measurement group_id="O2" value="36" spread="12" lower_limit="24" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)at 6 Months</title>
        <description>Left Ventricular Ejection Fraction as measured by Magnetic Resonance Imaging (MRI)at 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Medical Therapy</title>
            <description>This consisted of standard treatment of heart failure as per international guidelines. Treatment generally included use of ace-inhibitors (captopril, enalapril, lisinopril, perindopril, ramipril), beta blocker (metoprolol, carvedilol, bisoprolol) and aldosterone antagonists (spironolactone). Obviously actual combination dose and type of drug used dependent on patient comorbidity and tolerance.</description>
          </group>
          <group group_id="O2">
            <title>Radiofrequency Ablation</title>
            <description>Patients underwent isolation of the pulmonary veins with radiofrequency ablation. This was performed a maximum of 2 times to try to acheive sinus rhythm. All patients also received background heart failure treatment as per international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)at 6 Months</title>
          <description>Left Ventricular Ejection Fraction as measured by Magnetic Resonance Imaging (MRI)at 6 months</description>
          <units>percentage of blood ejected in one beat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" spread="7" lower_limit="39" upper_limit="53"/>
                    <measurement group_id="O2" value="41" spread="11" lower_limit="30" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma B-type Natriuretic Peptide (BNP) at Baseline</title>
        <description>Plasma B-type Natriuretic Peptide (BNP) measured at basline</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Medical Therapy</title>
            <description>This consisted of standard treatment of heart failure as per international guidelines. Treatment generally included use of ace-inhibitors (captopril, enalapril, lisinopril, perindopril, ramipril), beta blocker (metoprolol, carvedilol, bisoprolol) and aldosterone antagonists (spironolactone). Obviously actual combination dose and type of drug used dependent on patient comorbidity and tolerance.</description>
          </group>
          <group group_id="O2">
            <title>Radiofrequency Ablation</title>
            <description>Patients underwent isolation of the pulmonary veins with radiofrequency ablation. This was performed a maximum of 2 times to try to acheive sinus rhythm. All patients also received background heart failure treatment as per international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma B-type Natriuretic Peptide (BNP) at Baseline</title>
          <description>Plasma B-type Natriuretic Peptide (BNP) measured at basline</description>
          <units>picograms per millilitre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1846" spread="1687" lower_limit="159" upper_limit="3533"/>
                    <measurement group_id="O2" value="2550" spread="2150" lower_limit="400" upper_limit="4700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma B-type Natriuretic Peptide (BNP) at 6 Months</title>
        <description>Plasma B-type Natriuretic Peptide (BNP)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Medical Therapy</title>
            <description>This consisted of standard treatment of heart failure as per international guidelines. Treatment generally included use of ace-inhibitors (captopril, enalapril, lisinopril, perindopril, ramipril), beta blocker (metoprolol, carvedilol, bisoprolol) and aldosterone antagonists (spironolactone). Obviously actual combination dose and type of drug used dependent on patient comorbidity and tolerance.</description>
          </group>
          <group group_id="O2">
            <title>Radiofrequency Ablation</title>
            <description>Patients underwent isolation of the pulmonary veins with radiofrequency ablation. This was performed a maximum of 2 times to try to acheive sinus rhythm. All patients also received background heart failure treatment as per international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma B-type Natriuretic Peptide (BNP) at 6 Months</title>
          <description>Plasma B-type Natriuretic Peptide (BNP)</description>
          <units>picograms per millilitre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1931" spread="1671" lower_limit="260" upper_limit="3608"/>
                    <measurement group_id="O2" value="2354" spread="2632" lower_limit="-278" upper_limit="4986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Medical Therapy</title>
          <description>This consisted of standard treatment of heart failure as per international guidelines. Treatment generally included use of ace-inhibitors (captopril, enalapril, lisinopril, perindopril, ramipril), beta blocker (metoprolol, carvedilol, bisoprolol) and aldosterone antagonists (spironolactone). Obviously actual combination dose and type of drug used dependent on patient comorbidity and tolerance.</description>
        </group>
        <group group_id="E2">
          <title>Radiofrequency Ablation</title>
          <description>Patients underwent isolation of the pulmonary veins with radiofrequency ablation. This was performed a maximum of 2 times to try to acheive sinus rhythm. All patients also received background heart failure treatment as per international guidelines.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>heart failure hospitalisation</sub_title>
                <description>within 1 week of the procedure</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael MacDonald</name_or_title>
      <organization>NHS</organization>
      <phone>01412112000</phone>
      <email>michael.macdonald@nhs.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

